Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
IPO Year: 2001
Exchange: NASDAQ
Website: seagen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/16/2023 | $140.00 → $175.00 | In-line → Outperform | Evercore ISI |
| 2/16/2023 | $155.00 → $175.00 | Outperform → Strong Buy | Raymond James |
| 2/6/2023 | $162.00 → $141.00 | Outperform → Market Perform | SVB Securities |
| 11/21/2022 | $135.00 | Hold | Truist |
| 10/11/2022 | $177.00 → $178.00 | Market Perform → Outperform | BMO Capital Markets |
| 6/29/2022 | $220.00 | Outperform | Raymond James |
| 6/24/2022 | $169.00 | Market Perform | BMO Capital Markets |
| 2/16/2022 | $201.00 → $142.00 | Market Outperform | JMP Securities |
| 2/10/2022 | $165.00 → $150.00 | Neutral | Piper Sandler |
| 2/10/2022 | $154.00 → $132.00 | Sector Perform | RBC Capital Mkts |
15-12G - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
S-8 POS - Seagen Inc. (0001060736) (Filer)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Seagen Inc. (NASDAQ:SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company's Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American Society of Clinical Oncology (ASCO) and chairs the Women Who Conquer Cancer committee. "We are pleased to welcome Sandra to our Board of Directors given her extensive research and clinical trial experience, especially in HER2-positiv
Felix Baker, Ph.D., Appointed Chair of the Board Board Begins Search for New CEO Roger Dansey, M.D., Chief Medical Officer, Remains Interim CEO Seagen Inc. (NASDAQ:SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen's Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found. The Board had previously announced that Dr. Siegall was on a leave of absence and that it had formed a committee of independent directors
Seagen Inc. (NASDAQ:SGEN) today announced the appointment of Lee Heeson as Executive Vice President, Commercial International. Heeson has nearly 30 years of industry experience, and will have responsibility for the continued expansion of Seagen's Commercial operations in Europe, Canada and the rest of the world outside the United States. He will be a member of Seagen's Executive Committee and report to Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen. Heeson succeeds Tuomo Pätsi, who will retire effective February 4, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220201005129/en/Lee Heeson (Photo: Busine
Accomplished biotechnology executive brings over 40 years of commercial and leadership experience across multinational pharmaceutical and biotechnology companies to ShouTi ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the company's board of directors. "It is a true privilege to welcome Dan to ShouTi as Chairman of our board," said Raymond Stevens, Ph.D., Chief Executive Officer, ShouTi. "As an industry veteran with an outstanding track record in guiding companies across all stages of development an
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive
SC 13D/A - Seagen Inc. (0001060736) (Subject)
SC 13G/A - Seagen Inc. (0001060736) (Subject)
SC 13D/A - Seagen Inc. (0001060736) (Subject)
SC 13D/A - Seagen Inc. (0001060736) (Subject)
SC 13G/A - Seagen Inc. (0001060736) (Subject)
SC 13G/A - Seagen Inc. (0001060736) (Subject)
SC 13D/A - Seagen Inc. (0001060736) (Subject)
SC 13G/A - Seagen Inc. (0001060736) (Subject)
SC 13G - Seagen Inc. (0001060736) (Subject)
SC 13G/A - Seagen Inc. (0001060736) (Subject)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR) Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ:SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, fo
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i
Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance Pfizer Inc. (NYSE:PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ:SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete
– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma – – Preclinical data presented for novel antibody-drug conjugate SGN-35T – Seagen Inc. (NASDAQ:SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,
-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic Urothelial Cancer after EV-302 Trial Demonstrates Near Doubling of Median Overall Survival- -Proposed Pfizer Transaction On-Track and Anticipated to Close in Late-2023 or Early-2024, Subject to Closing Conditions, with Ongoing FTC Review and Recent EC Approval- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023. David Epstein, Chief Executive Officer of Seagen said, "Seagen continues to build momentum in 2
TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval and to support global regulatory applications Seagen Inc. (NASDAQ:SGEN) and Genmab A/S (NASDAQ:GMAB) announced results today from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after fi
– Late-breaking results from global Phase 3 confirmatory studies of PADCEV (EV-302) in locally advanced or metastatic bladder cancer and TIVDAK (innovaTV 301) in recurrent or metastatic cervical cancer to be included in the ESMO Communication Activities – Seagen Inc. (NASDAQ:SGEN) today announced the upcoming presentation of detailed results from two pivotal Phase 3 studies at the ESMO Congress 2023. Results from the EV-302 study of PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) in locally advanced or metastatic urothelial cancer (la/mUC) in the first-line setting will be presented during a Presidential Symposium at the Congress. Seagen will also present results from the
Seagen Inc. (NASDAQ:SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen is
– Trial results to be submitted for presentation at upcoming medical meeting – Seagen Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE:4503) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab) versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body. The EV-302 trial enrolled patients with previously untreated la/mUC who were eligible for cisplatin- or carboplatin-containing chemotherapy rega
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
4 - Seagen Inc. (0001060736) (Issuer)
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i
Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance Pfizer Inc. (NYSE:PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ:SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete
-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic Urothelial Cancer after EV-302 Trial Demonstrates Near Doubling of Median Overall Survival- -Proposed Pfizer Transaction On-Track and Anticipated to Close in Late-2023 or Early-2024, Subject to Closing Conditions, with Ongoing FTC Review and Recent EC Approval- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023. David Epstein, Chief Executive Officer of Seagen said, "Seagen continues to build momentum in 2
Seagen Inc. (NASDAQ:SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen is
-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23- -Strong PADCEV® Growth Driven By Combination First-Line Advanced Urothelial Cancer Launch; Record ADCETRIS® Performance with Overall Survival Benefit Demonstrated in the ECHELON-1 Trial Added to Label- -Three Registrational Trial Readouts for PADCEV, TUKYSA® and TIVDAK® Anticipated in 2H23- -Initiated Phase 3 Trial for Disitamab Vedotin and Expect to Initiate Phase 3 Trial of SGN-B6A by Year End- -Proposed Acquisition by Pfizer Progressing Towards Close in Late 2023 or Early 2024- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financi
Seagen Inc. (NASDAQ:SGEN) today announced that it will report its second quarter 2023 financial results on Wednesday, August 2, 2023. Given the previously announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Founded 25 years ago, Seagen Inc. is a global biotechnology company that discovers, develops, manufactures and commercializes targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. Our colleagues work together with urgency to improve and extend the lives of people living with cancer. An ADC technology trailblazer, approximately one-third of FDA-approved and marketed ADCs use Seagen technology. Seagen
-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer- -Presented Data at AACR on Multiple Targeted Cancer Pipeline Assets Highlighting Emerging Next-Generation Antibody Drug Conjugate (ADC) Technologies- -Previously Announced Agreement to be Acquired by Pfizer with Transaction Expected to Close Late 2023 or Early 2024- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023. The Company also highlight
Seagen Inc. (NASDAQ:SGEN) today announced that it will report its first quarter 2023 financial results on Thursday, April 27, 2023. Given the recently announced agreement to be acquired by Pfizer Inc., Seagen will not be hosting a conference call. About Seagen Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twit
Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion Proposed combination enhances Pfizer's position as a leading company in Oncology Seagen's medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer's Oncology portfolio Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030 Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today Pfizer Inc. (NYSE:PFE) and Seagen Inc. (NASDAQ:SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a gl
-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion- -TUKYSA Granted FDA Accelerated Approval for Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer- -ADCETRIS Received Pediatric Indication with FDA Approval for Children with Previously Untreated High Risk Hodgkin Lymphoma- -Multiple Key Milestones Anticipated in 2023, including Potential Label Expansion, Key Data Readouts and Additional International Launches for Current Products- -Conference Call Today at 4:30 p.m. ET- Seagen Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022. The Com
Evercore ISI upgraded Seagen from In-line to Outperform and set a new price target of $175.00 from $140.00 previously
Raymond James upgraded Seagen from Outperform to Strong Buy and set a new price target of $175.00 from $155.00 previously
SVB Securities downgraded Seagen from Outperform to Market Perform and set a new price target of $141.00 from $162.00 previously
Truist initiated coverage of Seagen with a rating of Hold and set a new price target of $135.00
BMO Capital Markets upgraded Seagen from Market Perform to Outperform and set a new price target of $178.00 from $177.00 previously
Raymond James initiated coverage of Seagen with a rating of Outperform and set a new price target of $220.00
BMO Capital Markets initiated coverage of Seagen with a rating of Market Perform and set a new price target of $169.00
JMP Securities reiterated coverage of Seagen with a rating of Market Outperform and set a new price target of $142.00 from $201.00 previously
Piper Sandler reiterated coverage of Seagen with a rating of Neutral and set a new price target of $150.00 from $165.00 previously
RBC Capital Mkts reiterated coverage of Seagen with a rating of Sector Perform and set a new price target of $132.00 from $154.00 previously